List/Grid

Oncology Subscribe to Oncology

Genetic cause of common breast tumors found

Genetic cause of common breast tumors found

A multi-disciplinary team of scientists from the National Cancer Centre Singapore, Duke-NUS Graduate Medical School Singapore, and Singapore General Hospital have made a major breakthrough in understanding the molecular basis of fibroadenoma, one of the most common breast tumors diagnosed in women. Continue reading

Targets for immunotherapy in early-stage breast cancer

Targets for immunotherapy in early-stage breast cancer

Yale Cancer Center researchers used a new molecular analysis tool to accurately detect the level of an important target for immunotherapy in early-stage breast cancers. The diagnostic test, using RNAScope, measures the amount of PD-L1 (programmed death ligand 1) mRNA in routine formalin-fixed cancer tissues and is devoid of many of the technical issues that plague antibody-based detection methods that have yielded conflicting results in the past. PD-L1 is the target of several novel immune stimulatory therapies in clinical trials Continue reading

Wake-up call for more research into cell metabolism

Wake-up call for more research into cell metabolism

More scientific research into the metabolism of stromal support cells and immune cells — and the role of the metabolism of these cell types in the development of diseases — could open new therapeutic avenues for diabetes, inflammatory conditions and cancer. That was the conclusion of a review article by scientists from VIB and KU Leuven in the leading journal Nature Continue reading

Proton therapy has advantages over IMRT for advanced head, neck cancers

Proton therapy has advantages over IMRT for advanced head, neck cancers

A new study by radiation oncologists at Mayo Clinic comparing the world’s literature on outcomes of proton beam therapy in the treatment of a variety of advanced head and neck cancers of the skull base compared to intensity modulated radiation therapy (IMRT) has found that proton beam therapy significantly improved disease free survival and tumor control when compared to IMRT. Continue reading

Cetuximab or bevacizumab with combi chemo equivalent in KRAS wild-type MCRC

Cetuximab or bevacizumab with combi chemo equivalent in KRAS wild-type MCRC

For patients with KRAS wild-type untreated colorectal cancer, adding cetuximab or bevacizumab to combination chemotherapy offers equivalent survival, researchers said at the ESMO 16th World Congress on Gastrointestinal Cancer in Barcelona. “The CALGB/SWOG 80405 trial was designed and formulated in 2005, and the rationale was simple: we had new drugs –bevacizumab and cetuximab– and the study was designed to determine if one was better than the other in first-line for patients with colon cancer,” said lead study author Alan P. Venook, distinguished Professor of Medical Oncology and Translational Research at the University of California, San Francisco, USA Continue reading

Phase III trial shows improved survival with TAS-102 in metastatic colorectal cancer refractory to standard therapies

Phase III trial shows improved survival with TAS-102 in metastatic colorectal cancer refractory to standard therapies

The new combination agent TAS-102 is able to improve overall survival compared to placebo in patients whose metastatic colorectal cancer is refractory to standard therapies, researchers said at the ESMO 16th World Congress on Gastrointestinal Cancer in Barcelona. “Around 50% of patients with colorectal cancer develop metastases but eventually many of them do not respond to standard therapies,” said Takayuki Yoshino of the National Cancer Centre Hospital East in Chiba, Japan, lead author of the phase III RECOURSE trial. Continue reading

False negative results found in prognostic testing for breast cancer

False negative results found in prognostic testing for breast cancer

A recent study evaluating HER2 testing in a large cohort of women with breast cancer found important limitations in the conventional way HER2 testing is performed in the US and internationally. Dartmouth-Hitchcock Norris Cotton Cancer Center physicians and researchers retested tumor samples from a large group of women and found that 22 out of 530 women had their tumor type incorrectly classified Continue reading

Breathalyzer test may detect deadliest cancer

Breathalyzer test may detect deadliest cancer

Lung cancer causes more deaths in the U.S. Continue reading

Barriers to obtaining gene expression profiling test heightened perceived value

Barriers to obtaining gene expression profiling test heightened perceived value

Barriers to obtaining gene expression profiling tests heightened their perceived importance among patients with early breast cancer who were deciding whether to have chemotherapy, a new study says. Gene expression profiling tests, such as Oncotype Dx, analyze the patterns of 21 different genes within cancer cells to help predict how likely it is that a women’s cancer will recur within 10 years after initial treatment and how beneficial chemotherapy will be to her. Dr Continue reading

Involving a genetic health care professional may improve quality, reduce unnecessary testing

Involving a genetic health care professional may improve quality, reduce unnecessary testing

A new Moffitt Cancer Center study published Thursday in Genetics in Medicine shows that counseling from a genetic health care provider before genetic testing educates patients and may help reduce unnecessary procedures. Up to 10 percent of cancers are inherited, meaning a person was born with an abnormal gene that increases their risk for cancer Continue reading